A synthetic piece of RNA enables human and mouse cells to produce normal levels of IKAP, despite the presence of the disease mutation, found researchers led by CSHL Professor Adrian Krainer, together with their collaborators at Ionis Pharmaceuticals.
The experiments, conducted in cells sampled from patients and in a mouse model of the disease, provide proof of the team's therapeutic concept.
Familial dysautonomia, or FD, occurs primarily in people of Ashkenazi Jewish ancestry. It impairs the development and function of the autonomic nervous system, causing problems with involuntary body functions, such as breathing, digestion, and blood-pressure regulation.
Alzheimers Disease
Alzheimer''s disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.
Advertisement
‘A therapeutic RNA molecule that corrects the error in genetic processing that leads to familial dysautonomia, a rare inherited neurodegenerative disorder has been discovered.’
Tweet it Now
Those affected carry a mutation in a gene called IKBKAP, which reduces cells' ability to produce the IKAP protein. The RNA-like molecule--known as an antisense oligonucleotide (ASO)--was injected into mice whose cells carry the human IKBKAP mutation that causes FD. It corrects an error in what scientists call RNA splicing that prevents people with FD from manufacturing sufficient functional IKAP protein. A drug based on the same ASO might be used to overcome the same mutation in people with familial dysautonomia, Krainer says. The findings, reported today in Nucleic Acids Research, come less than two years after the FDA approved nusinersen (marketed as Spinraza), an ASO that Krainer's lab developed in collaboration with Ionis Pharmaceuticals for the treatment of another neurodegenerative disorder called spinal muscular atrophy (SMA).
In their work on SMA, Krainer's team had shown that an ASO designed to bind to an RNA near a defective splice site could correct splicing and induce production of functional, full-length protein. They followed the same strategy in the newly published research on FD.
They designed and screened dozens of ASOs that bind to IKBKAP's RNA, looking for one that most efficiently restored normal splicing. "We used the same chemistry as we did for Spinraza, because we know that drug is well tolerated and it's very effective and stable in the central nervous system," Krainer says.
![New Antibody Test to Detect Proteins Implicated in Neurodegenerative Conditions]( "New Antibody Test to Detect Proteins Implicated in Neurodegenerative Conditions")
The antibody that binds to the tau-proteins, acts like a magnifying glass, amplifying tau levels so that differences between individuals could be seen more easily.
The team demonstrated that when they administered the ASO to mice harboring the mutant human IKBKAP gene, it reached various tissues, including the nervous system, and corrected splicing. More importantly, it restored production of full-length IKAP protein. Further testing is needed to determine whether it will be appropriate to move the ASO into clinical trials. But following the success of nusinersen, Krainer is optimistic that his team has identified a promising strategy for potentially treating familial dysautonomia.
Source: Eurekalert
New Antibody Test to Detect Proteins Implicated in Neurodegenerative Conditions
The antibody that binds to the tau-proteins, acts like a magnifying glass, amplifying tau levels so that differences between individuals could be seen more easily.
Advertisement
The team demonstrated that when they administered the ASO to mice harboring the mutant human IKBKAP gene, it reached various tissues, including the nervous system, and corrected splicing. More importantly, it restored production of full-length IKAP protein. Further testing is needed to determine whether it will be appropriate to move the ASO into clinical trials. But following the success of nusinersen, Krainer is optimistic that his team has identified a promising strategy for potentially treating familial dysautonomia.
Source: Eurekalert
Mutant Prion Protein Helps Reveal Neurodegenerative Disease Mechanisms
Mutant sheep scrapie prion lacks a stretch of amino acids that may be essential for infection.
Advertisement
 Clumps of Neuron Killing Proteins Implicated in Neurodegenerative DisordersMutation in SOD1 leads to clumping of proteins that kill neuron cells in neurodegenerative diseases like ALS. Phosphorylation of SOD1 was found to reverse it. | Advertisement
|
Advertisement
Latest Research News
Utilizing microparticles for therapy could mark a significant milestone in the fight against multiple sclerosis (MS) and other autoimmune diseases.
A study revealed that children with drug-resistant epilepsy (DRE) had the highest survival rate beyond 10 years when they underwent cranial epilepsy surgery.
From childhood through adolescence, the brain constantly changes, and researchers are making strides in identifying a potential treatment target for neuropsychiatric disorders.
In Japan, babies born in 2022 was also a record low at 770,747, down 40,875 from 2021, revealed data.
The first direct evidence supported the main theory for how human memory is amalgamated during sleep.